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Abstract

GROUP VIA CALCIUM-INDEPENDENT PHOSPHOLIPASE A2 REGULATES BCL-XL
PROTEIN LEVELS IN MICE LUNG
By Sang-Jin Nam, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Masters of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2014
Major Director: Daniel H. Conrad, Ph.D
Professor
Microbiology and Immunology

With previous indication of the Group VIA phospholipase A2 (iPLA2β) enzyme
regulating ER-stress induced apoptosis in β-cells by regulating the anti-apoptotic protein
Bcl-xL via alternative splicing, our lab postulated iPLA2β to be utilizing a similar
mechanism to regulate apoptosis in mice lung. Our previous lab work has shown
implications of lung function compromise in iPLA2β-/- mice, and we speculated the cause
to be due altered lung architecture stemming from the attenuation of apoptosis. The
western blot analysis in this study suggested that iPLA2β is involved in the regulation of
Bcl-xL, but the mRNA ratios of the splice variants suggested that alternative splicing is
not the mechanism iPLA2β is utilizing for the regulation in our animal models.
Additionally, the observation and assessment of the lung morphology of the iPLA 2β-/-

and wild type mice suggested that iPLA2β does not play an integral role in lung
morphology.

Introduction

In multicellular organisms, part of survival is ironically dependent on death.
Apoptosis, also known as programmed cell death, is a physiological process that occurs
normally in multicellular organisms to maintain a balance in cellular proliferations by
having an impact on a variety of biological events. These events range from
embryogenesis and cellular homeostasis to disposal of harmful and damaged cells [1].
The term “apoptosis” was first used by John Kerr and colleagues in the early 1970’s to
refer to the features of the unique morphological observation of cell death [2].
Some of the characteristics of cells going through apoptosis are loss of cellular
contact with the matrix, nuclei condensation, plasma-membrane blebbing, cellular
shrinkage, DNA fragmentation and disintegration of mitochondria [1]. Due to apoptosis
having an integral role in many important biological events, abnormalities in the pathway
of apoptosis can lead to various pathological conditions such as cancer, cardiovascular
disease, autoimmune and neuronal disorders [3].
Apoptosis is triggered and regulated by a wide variety of factors and has
conserved genetic and biochemical pathways as it is an important part of maintenance
of homeostatic balance [4]. Some of the factors that induce apoptosis are death
receptor ligands, such as Fas-ligands and tumor necrosis factor (TNF) [5]. Ultraviolet
irradiation, bacteria, DNA damage, oxidative stress and ceramide treatment can also
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trigger apoptosis, while various growth factors can regulate the process [6]. Apoptotic
stimuli can lead to two pathways of apoptosis, which are the extrinsic pathway, also
known as the death receptor pathway, and the intrinsic pathway, also known as the
mitochondrial pathway [7]. A group of apoptosis regulating proteins, Bcl-2 related
protein family, mediates the intrinsic pathway, while extracellular signals from other cells
activate the extrinsic pathway [4].
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Bcl-2 family

Evidence of physiological cell death tied to genetics was first observed in
developmental studies in the 1980’s of the invertebrate organism, C. elegans. Genetic
studies lead to the discovery of genes necessary for regulation, execution and
resolution of apoptosis during the development stages of C. elegans such as egl-1, ced3, ced-4 and ced-9. Proteins derived from egl-1, ced-3 and ced-4 caused programmed
cell death, while the anti-apoptotic ced-9 protein prevented death of the cells destined to
die during the developmental stages of C. elegans. Studies on the mechanism of
programmed cell death flourished and mammalian homologue genes were discovered
with the discovery of these genes. One of the key regulator proteins of apoptosis, Bcl-2
protein, was discovered soon after as the mammalian homologue of Ced-9 [8].
First observed in B-cell lymphomas of humans [9], the B-cell
lymphoma/leukemia-2 (bcl-2) gene’s anti-apoptotic effects demonstrated the correlation
between the regulation of cell death and the development of tumors [10]. Over
expression of Bcl-2 in cytokine dependent cell lines inhibited cell death caused by
growth factor deprivation [6]. However, the promotion of cell proliferation was not
observed in these cells suggesting that cell death and cytokine stimulated cell
proliferation did not share a same mechanism [6]. These results suggested that cell
death is regulated by a molecular mechanism separate from the mechanism of cytokine
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stimulated cell proliferation, and for the first time demonstrated that abnormalities in the
regulation of cell death could lead to cancer development [6].
With the discovery of Bcl-2, the importance of the regulation of apoptosis was
demonstrated, which opened new doors and insight to cancer biology. The intense
studies in this field lead to discoveries of many different Bcl-2 related proteins [6]. These
apoptosis regulating proteins were soon categorized into one pro-survival subgroup and
two pro-apoptotic subgroups [11]. It is the interactions of these three subgroups of the
Bcl-2 related proteins on the mitochondrial outer membrane that subsequently regulate
apoptosis. Due to the utilization of the three functionally and structurally distinct
subgroups, the Bcl-2 protein family can be regarded as a tripartite apoptotic switch [12].
The factor that ties the members of the Bcl-2 related proteins into one family is the
conserved BH, short for Bcl-2 homology, domains they possess. There are four distinct
BH domains which correspond to the alpha-helical segments of the proteins and all
subgroups possess the BH3 domain [13]. The protein members of the pro survival/anti
apoptotic subgroup and the multi-domain effector proteins of the pro apoptotic subgroup
possess all four BH domains and form globular structures. These structures are formed
by surrounding one central hydrophobic core helix with a bundle of α helices, which
produce hydrophobic surface grooves generated by the folding of helices. The tertiary
structure provides the functionality of the proteins by allowing these grooves to be used
as vital interfaces for the interaction with the BH3 domain of pro-apoptotic members
[12].
Having their N-terminus face the cytosol, Bcl-2 related proteins carry their
hydrophobic membrane insertion domain on their C-terminus. The membrane insertion
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domain allows the proteins to integrate into the cytosolic side of the mitochondrial
membrane, endoplasmic reticulum and nuclear envelope. The orientation of the proteins
facing the cytosol allows the protein to interact with their associated proteins to function.
The localization of the Bcl-2 related proteins can vary [13]. The variance of localization
of the Bcl-2 related proteins can be due to their functions. For example, there are
indications of BAX, an apoptotic Bcl-2 related protein, traveling back and forth from the
cytosol to the outer mitochondrial membrane in healthy cells. They are suggested to be
retro-translocated to the cytosol by Bcl-xL and other pro-survival Bcl-2 related proteins
to prevent the accumulation of BAX thus preventing apoptosis [14].

Pro-apoptotic initiators

Pro-apoptotic mediators

Anti-apoptotic/Pro-

(BH3-only)

(Multi-domain)

survival

Bik, Bad, Bid, Bim, Bmf,

Bak, Bax, Bok

A1, Bcl-2, Bcl-B, Bcl-W,

Hrk, Noxa, Puma, tBID

Bcl-xL, Mcl-1

Figure 1. Bcl-2 related protein family

The pro-apoptotic subgroups of Bcl-2 related proteins consists of the BH3-only
proteins and the multi-domain pro-apoptotic proteins. Currently the BH3-only protein
subgroup is consisted of members including Bik, Bad, Bid, Bim, Bmf, Hrk, Noxa, Puma
and tBID, and the multi-domain pro-apoptotic protein subgroup members are composed
of Bak, Bax and Bok [15].
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Unlike the previously mentioned multi domain proteins, BH3-only proteins
possess one BH domain. Once activated by a cytotoxic signal, the BH3-only proteins
carry out their function by forming a complex with the pro-survival proteins by the
formation of a salt bridge between the conserved Asp residue and the conserved Arg
residue located in the BH1 domain of the pro-survival proteins [16]. While the BH3-only
proteins can carry out apoptotic function by neutralizing the pro-survival proteins, there
are also suggestions for a direct activation of the multi domain pro-apoptotic proteins by
these proteins [17]. Regardless of the mechanism of the protein, the subsequent effect
is the homo-oligomerization of the multi-domain pro-apoptotic proteins, BAK and BAX,
which leads to formation of pores in the outer mitochondrial membrane [18]. The pores
increase the permeability of the outer mitochondrial membrane leading to the release of
Smac and cytochrome c into the cytosol, which induces a series of cascades leading to
apoptosis [19].
The pro-survival Bcl-2 related proteins, consists of members including A1, Bcl-2,
Bcl-B, Bcl-W, Bcl-xL and Mcl-1. These proteins are antagonists of the BH3-only proteins
that prevents the effects of various cytotoxic stimuli by neutralizing the apoptotic BH3only proteins or by directly binding to the BH3 domain of activated BAK and BAX to
inhibit their pro-apoptotic function [20]. The competition between the BH3-only proteins
and the pro-survival proteins to regulate the multi domain pro-apoptotic proteins, BAK
and BAX, suggests that the relative ratio of the two proteins dictate the sensitivity or
resistance of the cell to apoptotic stimuli [21].
Alternative splicing of pre-mRNA is a common method of genes to encode for
different variants of proteins having different functions. This method is utilized by the
6

Bcl-x pre-mRNA to produce two distinct isoforms, Bcl-xL and Bcl-xS [22]. Our target
protein Bcl-xL is a longer isoform, 241 amino acid long in length, containing an internal
region of 63 amino acids that shows the greatest homology to Bcl-2. This internal region
is deleted in the shorter isoform Bcl-xS, which is 178 amino acid long, and shows to be
the reason for Bcl-xS to not have the same function as Bcl-xL [18][23]. Functionally BclxL prevents cell death, but Bcl-xS’s role in apoptosis is still unclear [24].

Figure 2. Bcl-x pre-mRNA is spliced into two splice variants, Bcl-xL (at
downstream 5’ splice site) and Bcl-xS (at upstream 5’ splice site) from Wilhelm et
al. with modification [25]

In most cases, the splice variant ratio of Bcl-xL to Bcl-xS is observed to be
shifted in favor of Bcl-xL, which subsequently showed increased expression levels of
Bcl-xL in a number of cancers and cancer cell lines. Observations of Bcl-xS splice
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variant increase and the induction of apoptosis of cancer cells also existed when the 5’splice sites of Bcl-xL were hindered with the treatment of antisense oligonucleotides
[26]. There is also an indication of ceramide shifting the splice variant ratio in favor of
Bcl-xS in human adenocarcinoma A549 cells [27]. The regulation and mechanism of
Bcl-x alternative splicing is not clearly defined, but with the indication of ceramide
having a potential role in this process an enzyme is postulated to be involved. That
enzyme is thought to be iPLA2β, a calcium-independent phospholipase A2 enzyme
which is observed in studies to cause apoptosis in β-cells using a novel mechanism
involving ceramide generation [28][29][30].
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Phospholipase A2

Phospholipase A2 (PLA2) is a superfamily of enzymes involved in diverse lipid
metabolism and disease progression [31][32][33]. In the late 19th century, the enzyme
was first discovered as a major component of snake venom [32]. With the improvement
of technology, researchers were able to purify different forms of PLA2s from an
assortment of sources ranging from old world and new world snake venoms to human
pancreatic enzymes. Depending on the disulfide bond patterns and structural motifs,
scientists were able to divide and expand the different PLA2s into 15 distinct groups
[32]. Furthermore, the groups were categorized into four types of PLA 2s depending on
their characteristics such as cytosolic cPLA2s, secreted sPLA2s, calcium-independent
iPLA2s and platelet-activating factor acetylhydrolases [34]. Despite the diversity in
structure and function, all the PLA2 enzymes are 40 to 99 percent identical in their
amino acid sequences [35].
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sn-2

Figure 3. Phospholipase A2 targets the sn-2 position of membrane
glycerophospholipids [36]

PLA2s target the sn-2 position of membrane glycerophospholipids, the second
carbon group of the glycerol backbone, to catalyze the release of free fatty acids such
as arachidonic acid and lysophospholipids, which play vital roles in various biological
activities [37]. For mammalians, the group of enzymes’ involvement can range from
smooth muscle contraction to the biosynthesis of prostaglandins and leukotrienes,
which plays an important role in signal transduction. In snake venom, the enzymes are
toxic and are involved in the digestion and interference of normal physiological
processes of their prey. Due to PLA2 enzymes having great diversity in biological roles,
they are the one of the most studied group among the phospholipases [38].
Group VI (GVI) PLA2 enzymes were categorized as Ca2+-independent PLA2s
(iPLA2) due to their characteristics of not requiring calcium ions for catalytic activities
unlike their related PLA2 enzymes [39]. The subgroup of iPLA2 enzymes, which are
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classified into six distinct isoform groups, are the most recently described and the least
well characterized subgroup of PLA2 enzymes [40]. Out of the six isoforms, GVIA was
the first member of the iPLA2 family to be purified from macrophages in 1994 and is the
best characterized iPLA2 enzyme [41].
Group VIA PLA2, also known as iPLA2β, has a mass of 85 to 88 kDA and contains
a linker region, a catalytic domain with a lipase motif (GXSXG sequence) and 7 to 8
ankyrin repeats [39][33], and is mainly found in the cytosol of resting cells [42]. Recent
finding of iPLA2β’s ability to translocate to the membranes of the endoplasmic reticulum
and mitochondria suggest that the enzyme also possesses a targeting sequence, which
has not been identified yet [40]. This enzyme is suspected to be regulated through a
variety of mechanisms involving ATP binding, caspase cleavage, calmodulin, and quite
possibly by protein aggregation utilizing its ankyrin repeats [43].
Possessing lysophospholipase activity along with transacylase activity, iPLA 2β’s
catalytic activities are carried out by the serine residue in the lipase motif at the active
site [33]. Like its related PLA2 family members, iPLA2β cleaves the sn-2 position ester
bond of membrane phospholipids, but exhibits no preference towards arachidonic acids
in the sn-2 position [43]. The roles of iPLA2β are still to be defined, but with the recent
generation of iPLA2β deficient mice allowing extensive research, recent studies
including Dr. Barbour’s work has indication that iPLA2β has a role in phospholipid
remodeling, the maintenance of phosphatidylcholine mass, and signal transduction
[31][40][34]. Having roles in these physiological activities, studies suggest that iPLA 2β
can have diverse roles depending on different cell types, subsequently having important
roles in apoptosis, bone formation, insulin secretion and sperm motility [43]. Few
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studies also suggest the enzyme’s involvement in pathological conditions such as
diabetes, Barth syndrome, ischemia and cancer [41].
The correlation of iPLA2β and apoptosis first surfaced from Dr. Kenneth Polonsky’s
group’s study [44]. The study indicated that in mouse insulinoma cell line MIN-6, ER
stress induced by inhibiting sarcoendoplasmic reticulum Ca2+-ATPase (SERCA)
triggered apoptosis due to the depletion of Ca2+ in the intracellular Ca2+ stores. The ER
stress induced apoptosis was triggered independent of the change in the intracellular
free Ca2+ concentration. However the trigger of apoptosis was dependent on a signal
caused by the depletion of ER Ca2+ stores that utilized a lipoxygenase pathway of
arachidonic acid generation, which implied that a PLA2 enzyme was involved [40][44]. A
different study involving Fas-induced apoptosis of human leukemic U937 cells by Dr.
Ichiro Kudo and colleagues [45] also implied the correlation of iPLA 2β and apoptosis
[40]. Reports from this study indicated that Fas-related arachidonic acid release related
to Fas-induced apoptosis was dependent on iPLA2, and that the inhibition of iPLA2β
delayed Fas-induced apoptosis while the inhibition of cPLA2 and sPLA2 had no effect
[45].
Recent studies with INS-1 cells by Dr. Ramanadham and colleagues
[28][29][30][40] indicated a correlation of iPLA2β and apoptosis. In these studies,
causing ER stress with thapsigargin was shown to promote the release of apoptogenic
factors such as cytochrome c and Smac from the mitochondira, and the accumulation of
these factors were observed to be amplified in iPLA2β-overexpressing cells [40]. The
correlation of the accumulation of factors known to trigger the intrinsic apoptotic
pathway and the expression levels of iPLA2β suggested that iPLA2β is likely to be
12

involved in the activation of the ER stress-induced apoptosis [40]. In these studies, the
inhibition or knockdown of iPLA2β in β-cells reduced the induction of Neutral
Sphingomyelinase-2 (NSMase2) which subsequently prevented ceramide accumulation.
After observing a prevention of cytochrome c release following the inhibition of iPLA 2β
and NSMase2, ceramide generation which is induced by iPLA 2β, was suggested to
cause apoptosis in the INS-1 cells [28][29][30][40].
In the study with A549 cells [27], ceramide was shown to promote apoptosis by
shifting the alternative splicing of Bcl-x pre-mRNA in favor of Bcl-xS at the expense of
decreasing the levels of Bcl-xL. This observation and the observation made in the
previously mentioned study with INS-1 cells [28][29][30][40] prompted our lab to
postulate that iPLA2β might be regulating apoptosis via regulating Bcl-xL with ceramide.
In previous studies, our lab was able to obtain preliminary data from a study which the
manuscript is submitted to support this postulation. INS-1 cells treated with thapsigargin
to induce ER-stress exhibited significantly lower levels of Bcl-xL protein, and also
showed a shift in alternative splicing towards Bcl-xS. Further investigation of ceramide’s
effect on Bcl-x alternative splicing in INS-1 cells suggested that iPLA2β regulates Bcl-x
splicing through both a ceramide dependent mechanism and a ceramide-independent
mechanisms that utilizes the arachidonic acid or its metabolites. These observations
further supported that iPLA2β regulates apoptosis in β-cells.
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Figure 4. Airway resistance assay for iPLA2β-/- and wild type mice

After the investigations from our previous studies, our lab postulated that iPLA 2β
might be regulating apoptosis in mice lung with the similar mechanism observed in βcell. This hypothesis was postulated due to previous unpublished data [Fig 4] from Dr.
Conrad’s and our lab’s study with iPLA2β-/- mice. An unexpected observation was made
during an airway resistance assay in the experiment observing the effects of house dust
mite induced asthma inflammation in the lungs of iPLA2β-/- and wild type mice. There
was an observation of lung function compromise in the iPLA 2β-/- mice compared to the
wild type mice prior to the inhalation of methylcholine during the airway resistance
assay [Fig 4]. The compromised lung function in iPLA2β-/- mice was thought to be
secondary to altered lung architecture due to changes in remodeling, which is a process
14

dependent on apoptosis [47]. With indication of iPLA2β being involved in inducing
apoptosis in β-cells as well as other cells [40], our lab speculated that the reduced
apoptosis due to lack of iPLA2β is causing altered remodeling and architecture of the
lung which subsequently compromises the lung function in our iPLA2β-/- mice.

15

Hypothesis

Based on the observation of lung function compromise in iPLA2β-/- mice from our
lab’s previous studies, we hypothesize that GVIA Phospholipase A 2 (iPLA2β) is involved
in inducing apoptosis by regulating the expression of Bcl-xL in mice lung via alternative
splicing.
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Materials and Methods

Animals and Tissue processing
Our experimental protocol was performed in accordance with regulations of the
Institutional Animal Care and Use Committee of Virginia Commonwealth University.
Wild type C57BL/6 mice (n = 5) were received from The Jackson Laboratory (Bar
Harbor, Maine), and the iPLA2β-/- mice (n = 4) were from the generated and maintained
colony at Virginia Commonwealth University originating from Dr. John Turk’s lab at
Washington University. The animal models used in this experiment were gender and
age matched, and were fed ad libitum laboratory chow. With the help of Dr. Norbert F.
Voelkel’s lab, one-half of the fresh lung tissue was snap frozen for protein and RNA
analysis, and the other one-half was fixed by intratracheal infusion of 4% phosphatebuffered formalin at a pressure of 23 cmH2O for histological examination.

Identification of knockout mice
For the identification of the knockout mice, genotyping of the alleles were done
with the isolated genomic DNA of the mice tail. Tail tissue samples size of 0.5 cm from
each mouse were used with the DirectPCR Lysis Reagent kit (Viagen Biotech). The
samples used for the polymerase chain reaction (PCR) amplification were prepared in
accordance to the manufacturer’s protocols. For the PCR analysis of the genomic DNA,
17

the 1400 bp wild type iPLA2β allele was assessed using a primer mix containing Neo
primer (5’ TCG CCT TCT ATC GCC TTC TTG AC 3’) and wild type-antisense primer (5’
CTC CGC TTC TCG TCC CTC ATG GA 3’). The 400 bp knockout allele was assessed
using primer mix containing the wild type sense primer (5’ AGC TTC AGG ATC TCA
TGC CCA TC 3’) and MaEx-antisense primer (5’ GGG GCC TCA GAC TGG GAA TC
3’). The prepared samples were put through 35 cycles of PCR amplification after being
incubated at 95oC for 2 minutes for complete denaturing and activation of the DNA
polymerase. Each cycle consisted of 30 seconds of denaturing of the template strands
at 95oC, 30 seconds of annealing of the DNA primer at 56.5oC and 3 minute of
elongation of the copy strands at 72oC. The PCR samples were separated and
visualized by an agarose gel electrophoresis method. SYBR® Gold Nucleic Acid Gel
Stain (Invitrogen) was used for the staining of the separated bands, and the bands at
1400 bp and 400 bp were used to identify the wild type allele and knockout allele
respectively.

Preparation of the lung protein samples
Frozen lung tissues from each mouse were cut into a size of 0.5 cm with fresh
razor blades. Each tissue samples were solubilized in separate test tubes filled with
CelLyticTM MT buffer (Sigma-Aldrich) for 45 minutes on ice. Once the tissue was
homogenized in the buffer, the homogenates were centrifuged at 1000 x g for 20
minutes in a 4oC room. The retrieved protein samples were stored in a -80oC freezer.
The protein concentration of each lung sample was obtained using a protein assay kit
(Bio-Rad), and the sample protein size of 150 µg was assessed to be used for the
18

western blot analysis. Before the loading of the samples on to the SDS-PAGE gel, 150
µg of each sample was added into 4X SDS-PAGE sample buffer and was denatured by
heating the samples for 10 minutes at 95oC.

Western blot analysis
The purified and reduced proteins were separated via sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). The reducing SDS-PAGE gel
consisted of a 6% acrylamide stacking gel on top of a 10% acrylamide separating gel.
The prepared proteins were separated against the KaleidoscopeTM (Bio-Rad) protein
ladder in 1X Tris/Glycine/SDS Electrophoresis running gel buffer (Bio-Rad) consisting
25 mM Tris-HCl, pH8.3, 200 mM glycine, 0.1% (w/v) SDS and water. The separated
proteins on the SDS-PAGE gel were transferred via method of electroblotting onto
nitrocellulose membrane. The protein transferred membrane was treated with a blocking
buffer consisting of 5% diluted non-fat dry milk in Tris-buffered saline (TBS) 0.05%
tween solution for 1 hour with gentle rocking at room temperature. The non-specific
binding blocked membranes were immunoblotted with primary antibodies overnight in a
4oC room followed by incubation of horseradish peroxidase (HRP) linked secondary
antibodies for 1 hour at room temperature. Bcl-xL protein was probed with rabbit
primary antibody (BD PharmingenTM) diluted to 1:1000 in 5% non-milk solution, and αtubulin protein was probed with mouse monoclonal IgM (Santa Cruz) diluted to 1:200 in
5% non-milk solution. Bcl-xL was detected with HRP-conjugated Goat anti-rabbit
(Pierce) antibody diluted to 1:5000, and α-tubulin was detected with HRP-conjugated
rabbit anti-mouse IgM antibody (Pierce) diluted to 1:10,000. The immunoblotted proteins
19

were then visualized using the SuperSignal West Femto Chemiluminescent Substrate
(PierceTM), and the band intensities were analyzed using ChemiDocTM XRS+ System
(Bio-Rad) and Image LabTM software (Bio-Rad).

RNA extraction, PCR and RNA analysis
TRIZOL® LS Reagent (Invitrogen) was used for RNA extraction from lung tissue
samples. The protocol was done in accordance to the manufacturer’s instruction of
homogenization of the tissue, phase separation of the homogenized samples, RNA
precipitation and RNA washing. The obtained mRNA samples were quantified using a
spectrophotometer instrument (NanoDrop) by getting the absorbance ratio of 260
nm/280 nm. With the ratio’s being above 1.8 for every samples, the purity of each
samples were accepted. The quantification of each sample determined the mRNA
sample size of 0.08 µg to be used for the reverse transcriptase polymerase chain
reaction (RT-PCR). The ThermoScriptTM Reverse Transcriptase kit (Invitrogen) was
used for the RT-PCR to produce a cDNA of the obtained mRNA, and the protocol was
carried out according to the manufacturer’s instructions. In the end, the non-specific
endonuclease (RNase H) was added and incubated at 37oC for 20 minutes to remove
RNA complementary to the cDNA. Bcl-x forward primer (5’ CCA GCT TCA CAT AAC
CCC AG 3’) and Bcl-x reverse primer (5’ CCG TAG AGA TCC ACA AAA GTG TC 3’)
were used for the RT-PCR. The samples of cDNA were then stored in a -80oC freezer.
The cDNA samples from each mouse were used for the PCR amplification for the
quantification of Bcl-xL and Bcl-xS expression levels in each lung sample via
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polyacrylamide gel electrophoresis. AccuPrimeTM Taq DNA Polymerase kit (Invitrogen)
was used for the amplification of the cDNA in accordance to the manufacturer’s
protocol. The prepared samples were put through 35 cycles of PCR amplification after
being incubated at 94oC for 2 minutes for complete denaturing and activation of the
DNA polymerase. Each cycle consisted of 30 seconds of denaturing of the template
strands at 94oC, 30 seconds of annealing of the DNA primer at 54oC and 1 minute of
elongation of the copy strands at 68oC.
SDS-PAGE method was utilized for the quantification of Bcl-xL and Bcl-xS
expression levels. 8% polyacrylamide gel was used for the separation of 5 µL of the
PCR products which was ran against a 100 bp DNA ladder (New England BioLabs) at
110 volts in 0.5X Tris/Borate/EDTA (TBE) buffer solution. SYBR® Gold Nucleic Acid Gel
Stain (Invitrogen) diluted in TBE solution was used for the staining of the separated
bands, and the band intensities were analyzed using ChemiDocTM XRS+ System (BioRad) and Image LabTM software (Bio-Rad).

Morphological assessment
With the assistance of Dr. Voelkel’s lab, the lungs were fixed by intratracheal
infusion of 4% phosphate-buffered formalin at a pressure of 23 cmH2O. The tissues
were then sectioned at a thickness of 2 µm after being embedded in paraffin, and
stained with hematoxylin and eosin. The lung sections were from 4 iPLA2β knockout
mice and 4 wild type mice for morphological observation under light microscopy. Dr.
Voelkel’s lab was gracious for granting access to their lab’s Axio Imager A1 (Zeiss) and
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AxioVision (Zeiss) microscopy software for obtaining lung field images of the tissue
sections.
The Mean Linear Intercept (MLI) of the lung sections were obtained in reference
to the method of Mizuno et al [48]. Ten random images of lung fields per tissue section
were captured at magnification of X400. 2 diagonal lines connecting each corner of the
lung field image were drawn using the ImageJ software to measure the line intercepts of
septal wall of the lung. This process was done for every lung field image, and the
number of Intercepts for the 2 diagonal lines were averaged for every individual lung
tissue sections. The MLI of each lung tissue section was calculated by dividing the
length of the diagonals by the mean septum intercept count. The length of the diagonal
lines were measured by the ImageJ software.

Statistical analysis
Results are expressed as means ± standard error. The numerical data were
analyzed in a type 2 two tailed t-test in Microsoft Excel. It was determined that at pvalue less than 0.05 to be significant.
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Results

1400 bp
W.T. allele

400 bp
K.O. allele

Figure 5. Genotyping of the alleles confirms the proper knockout of iPLA2β in the
proposed knockout mice. Identification of the knockout and wild type mice was done
from the genomic DNA’s from tail biopsies of the animal models. Genotyping was
performed by PCR analysis, and the 1400 bp wild type allele was detected in 5 mice
while the 400 bp knockout allele was detected in 4 mice. This control experiment
allowed us to confirm and work with the proper animal models. (iPLA2β-/- mice, n = 4,
control mice, n = 5)
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Figure 6. Bcl-xL to tubulin ratios show that Bcl-xL protein levels are higher in the
iPLA2β-/- mice than wild type mice. (a) 150 ug of protein from each mice lung sample
was used for western blot analysis. (b) The ratios of Bcl-xL to tubulin protein from the
western blot analysis represent the protein levels of Bcl-xL in the knockout and wild type
mice. Protein analysis was the first step in finding a correlation of iPLA2β and Bcl-xL
protein levels, and Bcl-xL protein levels were found to be higher in the iPLA2β-/- mice
lung compared to the wild type mice lung. KO = iPLA2β-/- mice group, n = 3; WT = wild
type mice group, n= 4. Values are expressed as the means ± standard error. *, p < 0.05
(p-value = 0.036).
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iPLA2β regulates the protein level of Bcl-xL in mice lung
The protein levels of Bcl-xL in each mouse lung were quantified by western blot
analysis utilizing SDS-PAGE separation and ELISA assay. The Bcl-xL expression levels
are observed due to postulation of iPLA2β regulating Bcl-xL via alternative splicing. The
postulation was prompted due to the observation made in previous studies with iPLA2β
overexpressing INS-1 cells indicating the involvement of iPLA2β in β-cell apoptosis by
inducing the generation of ceramide [28]. Ceramide having implication for lowering the
ratio of Bcl-xL to Bcl-xS by affecting the alternative splicing of Bcl-x in A549 lung
adenocarcinoma cells [27] prompted us to hypothesize that iPLA 2β regulates Bcl-xL via
alternative splicing pre-mRNA through a novel mechanism possibly utilizing ceramide in
mice lung. In order to support this statement, it was essential for an initial measurement
of Bcl-xL protein levels in the tissue. The Bcl-xL levels in the iPLA2β knockout and wild
type mice were normalized to the levels of α-tubulin, a structural protein which protein
levels should be consistent in all samples.
Higher protein levels of Bcl-xL in the knockout mice compared to the wild type mice
were observed which supports our hypothesis. The mean ratio of Bcl-xL to α-tubulin
protein levels from the 3 knockout mice lung tissue was 0.691 ± 0.195, while the mean
ratio of the 4 wild type mice were observed to be lower at 0.251 ± 0.208 [Fig 6b]. These
ratios directly reflected the protein levels of Bcl-xL in the mice lung, and at the 0.05 level
of significance, the data rejected the null hypothesis with a p-value of 0.036. This
statistically significant data indicating a 3.3 times higher expression levels of Bcl-xL
protein in the iPLA2β knockout mice lung compared to the wild type mice lung supported
the first step of our hypothesis postulating that the presence of iPLA 2β promotes
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apoptosis by reducing the Bcl-xL protein levels. In the present study, we further
investigate our hypothesis by looking at the alternative splicing of Bcl-x pre-mRNA and
lung morphology to get a better idea of how iPLA2β is regulating Bcl-xL and to see if it is
has a correlation to levels of apoptosis in the mice lung.
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Figure 7. No significant difference in Bcl-x pre-mRNA alternative splicing were
found in iPLA2β-/- and wild type mice lungs. (a) The mRNA of Bcl-xL and Bcl-xS
expressed in the iPLA2β-/- and wild type mice were purified from each lung tissue
samples, and their cDNA were amplified via PCR and separated via SDS-PAGE. (b)
The quantification of the ratio of Bcl-xL to the Bcl-xS was to give a measurement of the
shift in Bcl-x pre-mRNA alternative splicing. RNA analysis was used to observe
correlation in the mice lung to the patterns observed in our lab’s unpublished work
showing iPLA2β regulating Bcl-xL protein levels via alternative splicing in β-cells. KO =
iPLA2β-/- mice group, n = 3; WT = wild type mice group, n= 4. Values are expressed as
the means ± standard error. (p-value = 0.41).

27

No significant evidence of iPLA2β regulating the alternative splicing of Bcl-x in mice lung
Observation of the expression levels of Bcl-xL protein could only provide supporting
evidence for iPLA2β regulating Bcl-xL protein expression, but could not provide
evidence for the postulated mechanism of regulating via alternative splicing. Few
studies indicated that a treatment with splice-switching oligonucleotides at the 5’ splice
site of Bcl-xL pre-mRNA increases the splicing of the Bcl-xS isoform at the expense of
reducing the levels of Bcl-xL mRNA [27][49]. Furthermore the previously mentioned
study with A549 cells [27] demonstrated that ceramide can be responsible for this
process. Indications of iPLA2β being involved in inducing ceramide generation via
induction of NSMase2 in β-cells [28][29][30][40] draw a correlation of a possible
involvement of iPLA2β in regulating Bcl-x pre-mRNA alternative splicing. This suggests
the shifting of Bcl-xL alternative splicing to Bcl-xS to be a possible method of iPLA2β for
regulating Bcl-xL protein levels in the mice lung. Therefore quantifying the mRNA levels
of the two splice variants of Bcl-x in respect to each other was necessary for a clearer
indication. The mRNA of Bcl-xL and Bcl-xS obtained from lung tissue samples were
converted into cDNA and amplified through PCR. The PCR products were separated by
polyacrylamide gel electrophoresis. The band intensities were quantified to assess the
mRNA levels of Bcl-xL and Bcl-xS in each animal model lung tissue. The comparison of
the ratios of Bcl-xL to Bcl-xS levels of the knockout mice to the wild type mice
represented a measurement of the shift in alternative splicing of Bcl-x pre-mRNA.
The knockout mice showed a ratio of 2.666 ± 0.882 compared to the wild type mice
ratio of 2.160 ± 0.612 [Fig 7b], and at the significance level of 0.05 the data could not
reject the null hypothesis with a p-value of 0.41. These results could not support our
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hypothesis of a possible involvement of iPLA2β in regulating Bcl-x pre-mRNA alternative
splicing, suggesting iPLA2β regulating Bcl-xL via a different mechanism.
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iPLA2β-/- MICE

W.T. MICE
a.

Figure 8. H&E stained lung sections from iPLA2β knockout and wild type mice
show no significant difference in lung morphology. Fixated tissues were embedded
in paraffin then sectioned (2 um). The sections were stained with hematoxylin and
eosin. Images shown are one of the 10 lung field of each animal model that best
represents the animal model’s MLI. Original magnification, X400.

30

45
40
35

MLI (µm)

30
25
20
15
10
5
0
KO

WT

Figure 9. Quantification of the mean linear intercept of the lung sections from
iPLA2β knockout and wild type mice show no significant difference in lung
morphology. Lung septum walls were counted for the measurement of MLI in the lung,
which gave an assessment for the average alveolar space sizes of the knockout and
wild type mice. Alveolar space sizes were assessed to see if there was a difference in
the lung morphology between the iPLA2β-/- and wild type mice lung. KO = iPLA2β-/- mice
group, n = 4; WT = wild type mice group, n= 4. Values are expressed as the means ±
standard error. (p-value = 0.093).
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No strong evidence for iPLA2β involved in maintenance of mice lung morphology
Indication of iPLA2β regulating the expression of Bcl-xL protein from our western
blot analysis lead to an investigation of iPLA2β’s effect on mice lung morphology. With a
phenotypic observation of lung function compromise in iPLA2β-/- mice [Fig 4], we
postulated a correlation of iPLA2β’s regulation of Bcl-xL to the maintenance of mice lung
morphology. Lung function is suggested to be correlated to the maintenance of
homeostasis and the structure of the lung [50][51], thus a possible alteration of structure
in the knockout lung was postulated be observed.
Unexpectedly, a visual assessment provided no obvious observable
morphological changes [Fig 8], therefore a quantitative assessment was necessary. As
a preliminary assessment for any structural changes, a simple quantification of alveolar
space sizes was adapted from Mizuno et al [48]. A widely used method of measuring
the changes in alveolar sizes is assessing the MLI of two groups of lung samples
[48][52][53][54]. MLI is a measurement of the mean distance between interalveolar
septal walls, and could be utilized to assess the alveolar space sizes of the mice lungs
[48]. The iPLA2β knockout lungs had an average MLI measurement of 33.786 ± 3.331
and the wild type lungs had an average measurement of 38.243 ± 3.251 [Fig 9], which
were not statistically significant. At a statistical significance of 0.05 could not be
observed to reject the null hypothesis with a p-value of 0.093.
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Discussion

Figure 10. Model of hypothesized mechanism of iPLA2β regulating Bcl-xL levels

The hypothesis postulated for this experiment was that iPLA 2β subsequently
regulates apoptosis in the mice lungs by regulating the expression levels of Bcl-xL via
alternative splicing [Fig 10]. The hypothesis stemmed from an unexpected observation
of compromised lung function in the iPLA2β knockout mice during a collaborative project
of Dr. Barbour and Dr. Conrad [Fig 4]. The lung compromise was thought to be due to
the changes in lung morphology of the iPLA2β knockout mice lung due to attenuated
apoptosis in the lung cells. Furthermore, the correlation of iPLA2β and Bcl-x alternative
splicing was postulated by our lab due to the observation made by Ramanadham et al
including Dr. Barbour [28][29][30] of ER stress induced prolonged activation of iPLA 2β in
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INS-1 β-cells triggered mitochondrial abnormalities which subsequently caused
apoptosis. The β-cell apoptosis is suggested to be carried out by iPLA2β’s induction of a
novel mechanism involving sphingomyelin hydrolysis leading to ceramide generation
[28]. The observation of β-cell apoptosis and the iPLA2β-dependent generation of
ceramide is important in linking iPLA2β, Bcl-x splicing and apoptosis, because of the
implication of ceramide causing a shift in alternative splicing of Bcl-x pre-mRNA in A549
lung adenocarcinoma cells [27]. The treatment of ceramide eventually lead to an
overexpression of Bcl-xS mRNA at the cost of reducing Bcl-xL mRNA subsequently
increasing apoptosis in the A549 cells [27], which is a similar mechanism we are
postulating iPLA2β to be utilizing in our animal models’ lung tissue to regulate Bcl-xL.
The results obtained through this experiment displayed patterns indicating our
hypothesis to be considered partially true. Our western blot analysis indicated an
increase in Bcl-xL protein levels in the iPLA2β-/- mice lung compared to the wild type
mice lung [Fig 6b], which implied iPLA2β’s involvement in down-regulating Bcl-xL. This
was the most significant observation made in our experiment. In the previously
mentioned study of ceramide-induced apoptosis with A549 cells [27], it was observed
that the decreased levels of the splice variant Bcl-xL mRNA via ceramide treatment
translated into decreased levels of Bcl-xL protein levels. Thus the decrease in levels of
Bcl-xL protein observed in our iPLA2β-/- mice suggested that iPLA2β might be regulating
Bcl-x alternative splicing via ceramide generation as we proposed. However, the results
from our mRNA ratio analysis of Bcl-xL to Bcl-xS [Fig 7b] did not support the postulated
mechanism for Bcl-xL regulation of our hypothesis. Our data from the MLI analysis [Fig
9] also did not support our proposal of iPLA2β to be involved in the maintenance of mice
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lung morphology which could have possibly indicated a correlation of iPLA 2β and
apoptosis regulation in mice lung.

Figure 11. Alternative model of iPLA2β effecting Bcl-xL protein levels

After rejecting the proposed mechanism of iPLA2β regulating Bcl-xL via
alternative splicing, the lab postulated a different probable mechanism [Fig 11].
Observing the levels of the non-receptor tyrosine kinase c-Src could provide a better
understanding of how iPLA2β regulates the Bcl-xL levels. Past studies [55][56][57][58]
show iPLA2 to be involved in the regulation of Ca2+ influx by activating store operated
Ca2+ channels (SOC) during Ca2+ store depletion in various cell types, including smooth
muscle cells. It is a possibility that in the absence of iPLA2β, cells activate and
upregulate different enzymes to respond to the depletion of intracellular Ca 2+ stores. In
a study with mouse embryo fibroblast [59] it was shown that Ca2+ influx induced by Ca2+
store depletion in Src- fibroblasts were significantly lower than the wild type fibroblasts.
This suggests that c-Src could also be a possible downstream activator of SOCs during
the depletion of internal Ca2+ stores. We postulate that c-Src could be upregulated in
the absence of iPLA2β as an alternative to cause Ca2+ influx during the depletion of
intracellular Ca2+ stores.
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The c-Src kinase could be the link in explaining the increased levels of Bcl-xL
protein in our iPLA2β-/- animal models. In a study with DHER14 and CSH12 cell lines
[60], treating the cells with a Src family kinase inhibitor and repressing c-Src expression
with Src antisense RNA down-regulated the Bcl-xL levels in addition to causing
apoptosis. Similar to these observations, we propose that c-Src kinase could possibly
be up-regulated and activated in our iPLA2β-/- mice lungs which is subsequently leading
an increased protein level of Bcl-xL in our knockout mice lungs. There have been
studies that demonstrated the importance of transcription factor families such as
STATs, NF-kB, Ets families for the regulation of the BCL2L1 gene [61], the gene of Bclx. In our case STAT-3, a possible downstream target protein of Src kinase [60], may be
involved in regulating Bcl-xL levels [62]. In the next steps of investigating the possible
mechanism of iPLA2β regulating Bcl-xL, our lab could compare the protein levels of
pp60c-Src in the wild type and iPLA2β-/- mice lung. Confirming whether iPLA2β has an
effect on c-Src kinase can have an implication of iPLA2β involving a JAK/STAT pathway
to regulate the expression levels of Bcl-xL in the mice lung.

Figure 12. Alternative model of iPLA2β regulating Bcl-xL protein levels utilizing
ubiquitin-proteasome system
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Another possible method of iPLA2β to be affecting the levels of Bcl-xL protein is
by targeting the turnover rate of the protein [Fig 12]. Observation of a difference in BclxL protein levels without a shift in alternative splicing suggests that iPLA2β to be
affecting the levels of Bcl-xL at the post translational stage of Bcl-xL. The ubiquitinproteasome system (UPS) is known to be involved in the regulation of wide variety of
cellular processes by degrading variety of regulatory proteins [63][64][65][66]. Among
the many cellular processes that UPS is involved, UPS is known to be involved in the
degradation of proteins that regulate apoptosis [63][64][65]. Involvement of iPLA2β in
UPS could be a possible mechanism in regulating the protein levels of Bcl-xL in mice
lung. In muscle cells it is suggested that arachidonic acid metabolites are involved in
inducing the expression of proteasomes and causing protein degradation [67].
Furthermore it is shown that inhibitors of PLA2 enzymes attenuate expressions of
proteasome which suggests that PLA2 enzymes along with other enzymes are essential
in inducing the ubiquitin proteasome system [67]. Arachidonic acid released by iPLA2β
could possibly be targeting proteasomes to degrade Bcl-xL proteins to subsequently
down-regulate Bcl-xL. The increased Bcl-xL protein levels observed in our knockout
mice lungs could possibly be due to the decrease in degradation of Bcl-xL protein
caused by the absence of iPLA2β.
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Figure 13. Alternative model of iPLA2β affecting lung function in mice

With our data suggesting no morphological changes to be observed in the
iPLA2β-/- mice lung to explain the lung function compromise, we postulate that iPLA 2β is
affecting the lungs at the physiological levels rather than the morphological level [Fig
13]. An experiment with iPLA2β-/- mice [68] suggested that iPLA2β plays an important
role in agonist-induced constriction and dilation in vascular smooth muscles and
endothelium by being involved in intracellular Ca2+ homeostasis. It was shown that
basal state of vessels displayed no significant difference in diameters between the
iPLA2β-/- and wild type mice, but iPLA2β-/- vessels displayed an increase sensitivity to
phenylephrine induced constriction displaying smaller diameter at maximum constriction
at a steady state while being insensitive to acetylcholine induced dilation [68]. This
suggests that our iPLA2β-/- animal model might be experiencing lung function
compromise due to the agonist-induced hypercontractility and attenuated endothelium38

dependent relaxation in airway smooth muscles of the lung. Hypercontractility and
abnormalities in relaxation of airway smooth muscles have been associated with
asthma [69] which causes lung function compromise in patients, and could be the case
for our iPLA2β-/- mice. This could explain the reason for the iPLA2β-/- house dust mite
mice model experiencing lung function compromise compared to the wild type even
before the treatment with the lung airway constricting methylcholine during the airway
resistance assay [Fig 4] of our previous study. This postulation is further supported by
the observation of the exacerbated difference in airway resistance between the iPLA 2β-/and wild type mice after the treatment of methylcholine. In order to assess the possibility
of abnormalities in relaxation of the iPLA2β-/- airway smooth muscles, further
investigation of vasopressin or nitric oxide (NO) production in the mice lung is
necessary. In studies [70][71] NO is found to induce relaxation in airway smooth muscle
cells, and looking into phosphorylation of NO synthases (NOS) can be a good indication
of a possible malfunction in NO production in the endothelium cells associated with
airway smooth muscle cells causing insensitivity to agonist-induced relaxation just as it
was proposed in the study with vessels of iPLA2β-/- mice [68]. In the study with iPLA2β-/vessels [68] they observed an inhibition of NO production and endothelial NOS (eNOS)
phosphorylation by an iPLA2 inhibitor. Western blot analysis of phospho-eNOS at
Ser1177 was used in their study [68], and a similar analysis in our animal model lungs
can give us an indication of any attenuated NO production levels to cause lung function
compromise in an iPLA2β knockout condition.
There is a possibility that our data was underestimating iPLA2β’s effect on Bcl-x
pre-mRNA alternative splicing due to a broad sample pool of mRNA which was taken
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from the lung tissue as a whole. Since we are postulating that iPLA 2β is possibly
involved in the functionality of airway smooth muscles and endothelial cells, it will be
worth repeating the mRNA quantification of Bcl-x isoforms with these specific lung cells.
The quantification with the specific lung cells relevant to lung functionality and
investigating c-Src kinase activity could clarify the mechanism of Bcl-xL regulation and
possibly pave pathways to further our current study.
In summary, our data from the present study suggest that iPLA2β regulates
protein levels of Bcl-xL in mice lung, and the data further confirms that iPLA2β regulating
alternative splicing of Bcl-x via ceramide is possibly a β-cell specific mechanism that is
not found be true in mice lung tissue. Although there was no evidence in our data of
iPLA2β regulating alternative splicing of Bcl-x pre-mRNA in mice lung as a whole, further
investigation is needed to discern if it is also the case for specific cells and tissue within
the lung such as airway smooth muscle and endothelial cells. Understanding the
mechanism utilized by iPLA2β in regulating Bcl-xL in cells and tissue that is relevant to
lung function, and iPLA2β’s effects on the physiology of the mice lung could possibly
lead to therapeutic targets for asthma and lung function compromise related diseases.
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